Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Not only will a company use a significant amount of capital to make the acquisition, but there are longer-term issues, such as the merging of two company cultures, Franz said in an interview with CNBC.
BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
After the change of name to Meidrix Biomedicals GmbH, the business areas will be continued and further expanded
GlaxoSmithKline plc today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
A 2013 study that analyzes IPO withdrawals between 1999 and 2004 found that about 13 percent returned later for a successful IPO, 36 percent turned again to raising capital privately, and 42 percent either merged or were acquired by other companies—another common strategy for biotechs. And about 11 percent filed bankruptcy.
Now that Bristol-Myers Squibb is acquiring Celgene, the company will largely disappear into Bristol-Myers Squibb, but a legacy of bold risk-taking and questionable price hikes remain.
Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.
Kindred Biosciences, Inc. today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share
The two companies inked a non-disclosure agreement on December 22, 2018 and amended it a day later. One of the things apparent is that the companies wanted to make a splash at the JPM conference.
Mirati Therapeutics, Inc. (Nasdaq: MRTX) announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share.